Yubo International Biotech Reports Decreased Net Loss and No Revenue in Q2 2025

Yubo International Biotech Limited reported its financial results for the second quarter of 2025, revealing a net loss of $249,722, a decrease from a net loss of $598,348 in the same period of 2024. For the six months ending June 30, 2025, the company recorded a net loss of $592,136, compared to a loss of $1,007,853 in the prior year. The company did not generate any revenue from product sales during the quarter, which is a significant change from the $3,488 reported in the second quarter of 2024. Operating expenses for the quarter were $249,699, down from $470,436 in the previous year, indicating a reduction in costs.

The company’s total assets decreased to $1,051,568 as of June 30, 2025, from $1,534,832 at the end of 2024. This decline was primarily driven by a reduction in cash and property, plant, and equipment. Current liabilities increased to $5,025,470, up from $4,721,749 at the end of 2024, largely due to an increase in accounts payable and accrued expenses. The accumulated deficit also widened to $7,326,775 from $6,660,811, reflecting ongoing operational challenges.

Strategically, Yubo International Biotech has made significant moves in its organizational structure, including the acquisition of Phoenix Club Bio-Medical Technology (Chengdu) Co., Ltd. in October 2023. This acquisition is part of the company's efforts to expand its product offerings and market presence. Additionally, the company has been focusing on its health management and maintenance service agreements, which began in the third quarter of 2023, although these have yet to contribute to revenue.

Operationally, Yubo International Biotech has not reported any significant customer growth or engagement metrics, as the company continues to navigate a challenging market environment. The total employee headcount remains stable, but the company has indicated a need for additional capital resources to sustain operations. As of June 30, 2025, the company had cash reserves of $10,416, which raises concerns about its ability to meet ongoing operational costs without further financing.

Looking ahead, Yubo International Biotech's management has acknowledged the need for additional capital to continue operations and is exploring options for equity and debt financing. The company has received a financial support commitment from its major shareholder, which is expected to provide necessary liquidity for the next 12 months. However, the ongoing losses and the lack of revenue generation raise substantial doubt about the company's ability to continue as a going concern without securing additional funding.